Leukemia and lymphoma target cell lines for cytotoxicity assays were selected based on the expression of the NK cell activating ligands RAE‐1 and MULT‐1 (detected via NKG2D) and CD155 (detected via DNAM1). This evidence concerns the gene CD226 and lymphoma.